Skip to content

Clinical Evaluation of the Zynex Blood Volume Monitor (CM-1500) in Healthy Male Adult Subjects During a Blood Draw

Clinical Evaluation of the Zynex Blood Volume Monitor (CM-1500) in Healthy Male Adult Subjects During a Blood Draw

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01646060
Enrollment
10
Registered
2012-07-20
Start date
2011-11-30
Completion date
2011-12-31
Last updated
2012-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Loss, Healthy

Keywords

blood, loss, healthy, volume, To evaluate the ability of the Zynex BVM to non-invasively detect blood loss in healthy subjects during a blood draw.

Brief summary

Zynex's blood volume monitor (BVM) is a non-invasive monitoring device to monitor blood volume and blood loss of a patient during surgery, post operatively and/or in recovery. This monitoring device will identify baseline blood volume and relative changes in blood volume using a specific algorithm to compare and review data already monitored during surgery, displaying blood volume and blood loss in real-time.

Interventions

DEVICECM-1500

Blood Volume Monitor

Sponsors

Zynex Monitoring Solutions
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Written informed consent * Male, 18-65 years of age * Subject is suitable for a blood draw of a pint of blood * Weighs at least 110 pounds

Exclusion criteria

* Subject has a heart condition that may interfere with the Zynex CM-1500 * Subject has unstable or untreated heart disease * Subject has been diagnosed with chronic fatigue syndrome * Subject is taking coumadin (warfarin), heparin, or other prescription blood thinners for at least 7 days prior to blood draw * Subject donated blood within 8 weeks prior to blood draw * Subject has high or low blood pressure on the day of blood draw * Subject hemoglobin \< 12.5 g/dL

Design outcomes

Primary

MeasureTime frame
Detect change in blood volume during blood draw15-30 minutes

Secondary

MeasureTime frame
Detect insidious bleeding15-30 minutes

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026